Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The prevention of perioperative atrial fibrillation has the potential to reduce mortality,
stroke, and hospital stays in patients undergoing thoracic surgery. Data from cardiac surgery
patients suggest that prevention of perioperative atrial fibrillation using an
anti-inflammatory agent, such as colchicine, is feasible. The COP-AF trial will assess
whether the administration of oral colchicine will reduce the incidence of perioperative
atrial fibrillation in patients undergoing major thoracic surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborators:
Hamilton Health Sciences Corporation McMaster University